Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013)

Halozyme Therapeutics' (HALO) quarterly Capital Leases came in at $2.6 million in Q3 2013, up 21.43% on a QoQ basis from $2.1 million in Q2 2013.

Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013) Analysis & Trends

Halozyme Therapeutics (HALO) has 2 years of Capital Leases data on file, last reported at $2.6 million in Q3 2013.

On a quarterly basis, Capital Leases changed N/A year-over-year to $2.6 million in Q3 2013; TTM through Sep 2013 was $2.6 million, a N/A change from a year earlier, with the FY2012 full-year figure at $1.4 million, changed N/A from the prior year.
Capital Leases for Q3 2013 stood at $2.6 million, up from $2.1 million in the prior quarter.
Over the last five years, Capital Leases for HALO reached as high as $2.6 million in Q3 2013 and fell as low as $1.4 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Halozyme Therapeutics	9.55 Bn	9.23 Bn	297.47 Mn

Download Data